By Stephen Simpson, CFA : The frustrating wait for the key driver at Lexicon Pharmaceuticals (NASDAQ: LXRX ) - a clinical development and marketing partner for LX4211 - goes on. While management spent a lot of time on its earnings call
Lexicon Pharmaceuticals , Inc. (NASDAQ: LXRX ) Q2 2014 Results Earnings Conference Call August 7 ..... this time, I would like to welcome everyone to the Lexicon Pharmaceuticals ’ Second Quarter Earnings Conference Call. All lines
background in cardiovascular disease and endocrinology, which is critical for the firm's LX4211 program. Lexicon Pharmaceuticals is a biopharmaceutical company that uses mouse genetics to discover the function of genes and find promising
Lexicon Pharmaceuticals ( LXRX -3.6% ) Q2 results : Revenues: $676K (+215.9%); Operating Expenses: $26.8M (-7.1%); Operating Loss
Lexicon Pharmaceuticals (NASDAQ: LXRX ): Q2 EPS of -$0.05 in-line. Revenue of $0.7M (+233.3% Y/Y) beats by $0.58M . Press Release Post your comment!
Gainers: ACST +16% . LXRX +13% . NQ +9% . USU +9% . AAL +6% . TXMD +5% . CAMT +5% . Losers: GIMO -33% . TCS -15% . PT -7% . Post your comment!
I guess I should address this to Morning Star but don't find a way. My question is how can you cover in analysis a stock such as LXRX with 149 employes and not cover in your analysis a stock such as HLS, makes me wonder about how you pick your stocks to analyse. Jack
Despite a pipeline, lexicon pharma does not look cheap. At a valuation today of nearly 900 million, and an expensive road to drug approval, we should all expect continuing dilution of this equity. To my mind, the only reason to invest is for a catalyst gap up. Their diabetes drug looks intriguing,
the criterion of "5 stars." I only got 6 stocks, none of them were familiar to me. Can this be right? Alumina AWCMY Buenaventure Mining BVN Fiat Group FIATY Lexicon Pharmaceuticals LXRX Petroleo Brasileiro SA Petrobras ADR BPR Posco PKX
Morningstar rating change from 4-5 Stars. Does anyone buy or sell, based on M rating changes?